ArticleUrologic oncology2021
Clinical value of
Article in Urologic oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Head-to-head comparison ofDiagnostic and interventional radiology (Ankara, Turkey) · 2024Pooled it
- Development and validation of prostate-specific membrane antigen-adjusted Prostate Imaging Reporting and Data System: A new approach to enhancing the accuracy of diagnosing treatment-naïve primary prostate cancer.Asian journal of urology · 2026Article
- [Innovative imaging techniques for urothelial carcinoma].Urologie (Heidelberg, Germany) · 2026Review
- PSMA-Based Radiopharmaceuticals in Prostate Cancer Theranostics: Imaging, Clinical Advances, and Future Directions.Cancers · 2026Review
- Dr. A. Cahid Civelek Exemplifies the Act of Integrating Patient Care, Staff Education, Research, and Global Knowledge Sharing.Molecular imaging and radionuclide therapy · 2025Article
- Management of clinical stage T3/T4 bladder cancer: a review.World journal of urology · 2025Review
- Nuclear Medicine and Molecular Imaging in Urothelial Cancer: Current Status and Future Directions.Cancers · 2025Review
- Performance ofiScience · 2024Article
- Elafibranor emerged as a potential chemotherapeutic drug for non-muscle invasive bladder cancer.Cell insight · 2024Article
- Assessing the Performance of 18F-FDG PET/CT in Bladder Cancer: A Narrative Review of Current Evidence.Cancers · 2023Review
- Editorial: Global excellence in nuclear medicine: North America.Frontiers in medicine · 2023Article
- Management of Bladder Cancer Patients with Clinical Evidence of Lymph Node Invasion (cN+).Cancers · 2022Review
- Positron Emission Tomography Molecular Imaging for Phenotyping and Management of Lymphoma.Phenomics (Cham, Switzerland) · 2022Review
- Head-to-head comparison of [European journal of nuclear medicine and molecular imaging · 2022Article
- Small cell carcinoma of the bladder: Review of pathogenesis, presentation, and management.Bladder cancer (Amsterdam, Netherlands)Review
- Synergy of PET and MR imaging in the local and regional staging of bladder cancer.Therapeutic advances in urologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
objectiveMetastatic bladder cancer is an aggressive disease that can often be difficult to diagnose and stage with conventional cross-sectional imaging. The primary objective of this study was to determine the clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose ( MATERIALS AND
methodsThis retrospective study enrolled patients with muscle-invasive, locally advanced and metastatic bladder cancer in a single institute evaluated with
resultsFifteen patients (4 for surveillance; 11 for restaging) underwent 34
conclusion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.